

Lynn R Webster

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1729639/publications.pdf>

Version: 2024-02-01

118
papers

4,555
citations

172457
29
h-index

106344
65
g-index

120
all docs

120
docs citations

120
times ranked

3855
citing authors

#	ARTICLE	IF	CITATIONS
1	Predicting Aberrant Behaviors in Opioid-Treated Patients: Preliminary Validation of the Opioid Risk Tool. <i>Pain Medicine</i> , 2005, 6, 432-442.	1.9	918
2	Risk Factors for Opioid-Use Disorder and Overdose. <i>Anesthesia and Analgesia</i> , 2017, 125, 1741-1748.	2.2	328
3	Naloxegol for Opioid-Induced Constipation in Patients with Noncancer Pain. <i>New England Journal of Medicine</i> , 2014, 370, 2387-2396.	27.0	292
4	Sleep-Disordered Breathing and Chronic Opioid Therapy. <i>Pain Medicine</i> , 2008, 9, 425-432.	1.9	283
5	An Analysis of the Root Causes for Opioid-Related Overdose Deaths in the United States. <i>Pain Medicine</i> , 2011, 12, S26-S35.	1.9	249
6	Alvimopan, a peripherally acting mu-opioid receptor (PAM-OR) antagonist for the treatment of opioid-induced bowel dysfunction: Results from a randomized, double-blind, placebo-controlled, dose-finding study in subjects taking opioids for chronic non-cancer pain. <i>Pain</i> , 2008, 137, 428-440.	4.2	133
7	Discerning suicide in drug intoxication deaths: Paucity and primacy of suicide notes and psychiatric history. <i>PLoS ONE</i> , 2018, 13, e0190200.	2.5	112
8	Hypoxemia in patients on chronic opiate therapy with and without sleep apnea. <i>Sleep and Breathing</i> , 2009, 13, 49-57.	1.7	105
9	A phase 2, double-blind, randomized, placebo-controlled, dose-escalation study to evaluate the efficacy, safety, and tolerability of naloxegol in patients with opioid-induced constipation. <i>Pain</i> , 2013, 154, 1542-1550.	4.2	102
10	Long-Term Safety of NGX-4010, a High-Concentration Capsaicin Patch, in Patients with Peripheral Neuropathic Pain. <i>Journal of Pain and Symptom Management</i> , 2010, 39, 1053-1064.	1.2	95
11	Consensus Recommendations on Initiating Prescription Therapies for Opioid-Induced Constipation. <i>Pain Medicine</i> , 2015, 16, 2324-2337.	1.9	95
12	A Randomized, Placebo-Controlled Trial of Lubiprostone for Opioid-Induced Constipation in Chronic Noncancer Pain. <i>American Journal of Gastroenterology</i> , 2015, 110, 725-732.	0.4	87
13	Review and Critique of Opioid Rotation Practices and Associated Risks of Toxicity. <i>Pain Medicine</i> , 2012, 13, 562-570.	1.9	76
14	Treatment Options for Failed Back Surgery Syndrome Patients With Refractory Chronic Pain: An Evidence Based Approach. <i>Spine</i> , 2017, 42, S41-S52.	2.0	74
15	Definitions and Outcome Measures of Clinical Trials Regarding Opioid-induced Constipation. <i>Journal of Clinical Gastroenterology</i> , 2015, 49, 9-16.	2.2	71
16	Long-term use of naldemedine in the treatment of opioid-induced constipation in patients with chronic noncancer pain: a randomized, double-blind, placebo-controlled phase 3 study. <i>Pain</i> , 2018, 159, 987-994.	4.2	65
17	Opioid-Induced Constipation. <i>Pain Medicine</i> , 2015, 16, S16-S21.	1.9	59
18	Understanding Buprenorphine for Use in Chronic Pain: Expert Opinion. <i>Pain Medicine</i> , 2020, 21, 714-723.	1.9	57

#	ARTICLE	IF	CITATIONS
19	Opioid Therapy and Sleep Disorders: Risks and Mitigation Strategies. Pain Medicine, 2015, 16, S22-S26.	1.9	51
20	Opioid formulations in development designed to curtail abuse: who is the target?. Expert Opinion on Investigational Drugs, 2009, 18, 255-263.	4.1	50
21	A Phase 2b, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Chronic Noncancer Pain. Pain Medicine, 2017, 18, 2350-2360.	1.9	46
22	Randomized, Double-Blind, Placebo-Controlled Study of the Abuse Potential of Different Formulations of Oral Oxycodone. Pain Medicine, 2012, 13, 790-801.	1.9	43
23	The Abuse Potential of Remoxy [®] , an Extended-Release Formulation of Oxycodone, Compared with Immediate- and Extended-Release Oxycodone. Pain Medicine, 2011, 12, 618-631.	1.9	39
24	The Relationship Between the Mechanisms of Action and Safety Profiles of Intrathecal Morphine and Ziconotide: A Review of the Literature. Pain Medicine, 2015, 16, 1265-1277.	1.9	37
25	Impact of Intravenous Naltrexone on Intravenous Morphine-Induced High, Drug Liking, and Euphoric Effects in Experienced, Nondependent Male Opioid Users. Drugs in R and D, 2011, 11, 259-275.	2.2	36
26	Analysis of Nausea in Clinical Studies of Lubiprostone for the Treatment of Constipation Disorders. Digestive Diseases and Sciences, 2017, 62, 3568-3578.	2.3	36
27	Current status and evolving role of abuse-deterrent opioids in managing patients with chronic pain. Journal of Opioid Management, 2011, 7, 235-245.	0.5	35
28	Overdose Deaths Demand a New Paradigm for Opioid Rotation: Table 1. Pain Medicine, 2012, 13, 571-574.	1.9	33
29	Acute Pain: Effective Management Requires Comprehensive Assessment. Postgraduate Medicine, 2014, 126, 59-72.	2.0	31
30	Long-Term Safety of Remoxy [®] (Extended-Release Oxycodone) in Patients with Moderate to Severe Chronic Osteoarthritis or Low Back Pain. Pain Medicine, 2011, 12, 755-760.	1.9	29
31	Current Regulations Related to Opioid Prescribing. PM and R, 2015, 7, S236-S247.	1.6	29
32	Obtaining Adequate Data to Determine Causes of Opioid-Related Overdose Deaths. Pain Medicine, 2011, 12, S86-S92.	1.9	27
33	Tolerability of NGX-4010, a capsaicin 8% dermal patch, following pretreatment with lidocaine 2.5%/prilocaine 2.5% cream in patients with post-herpetic neuralgia. BMC Anesthesiology, 2011, 11, 25.	1.8	27
34	Evaluation of the Tolerability of Switching Patients on Chronic Full μ -Opioid Agonist Therapy to Buccal Buprenorphine. Pain Medicine, 2016, 17, pnv110.	1.9	26
35	A Review of Forensic Implications of Opioid Prescribing with Examples from Malpractice Cases Involving Opioid-Related Overdose. Pain Medicine, 2011, 12, S59-S65.	1.9	25
36	Human Abuse Potential of the New Opioid Analgesic Molecule NKTR-181 Compared with Oxycodone. Pain Medicine, 2018, 19, 307-318.	1.9	25

#	ARTICLE	IF	CITATIONS
37	Long-Term Safety and Efficacy of Subcutaneous Methylnaltrexone in Patients with Opioid-Induced Constipation and Chronic Noncancer Pain: A Phase 3, Open-Label Trial. <i>Pain Medicine</i> , 2017, 18, 1496-1504.	1.9	24
38	Daclatasvir + asunaprevir + beclabuvir ± ribavirin for chronic <scp>HCV</scp> genotype 1â€infectd treatmentâ€naive patients. <i>Liver International</i> , 2016, 36, 189-197.	3.9	23
39	Pharmacogenetics and Personalized Medicine in Pain Management. <i>Clinics in Laboratory Medicine</i> , 2016, 36, 493-506.	1.4	23
40	Benzodiazepines in Long-Term Opioid Therapy. <i>Pain Medicine</i> , 2013, 14, 1441-1446.	1.9	22
41	The health insurance industry: perpetuating the opioid crisis through policies of cost-containment and profitability. <i>Journal of Pain Research</i> , 2015, 8, 153.	2.0	22
42	Current and future development of extended-release, abuse-deterrent opioid formulations in the United States. <i>Postgraduate Medicine</i> , 2017, 129, 102-110.	2.0	22
43	Assessment of Pharmacodynamic Effects Following Oral Administration of Crushed Morphine Sulfate and Naltrexone Hydrochloride Extended-Release Capsules Compared with Crushed Morphine Sulfate Controlled-Release Tablets and Placebo in Nondependent Recreational Opioid Users. <i>Pain Medicine</i> , 2013, 14, 1173-1186.	1.9	21
44	Analysis of opioid-mediated analgesia in Phase III studies of methylnaltrexone for opioid-induced constipation in patients with chronic noncancer pain. <i>Journal of Pain Research</i> , 2015, 8, 771.	2.0	20
45	A Randomized, Double-Blind, Double-Dummy Study to Evaluate the Intranasal Human Abuse Potential and Pharmacokinetics of a Novel Extended-Release Abuse-Deterrent Formulation of Oxycodone. <i>Pain Medicine</i> , 2015, 17, pnv020.	1.9	20
46	Efficacy and Safety of Dual-Opioid Therapy in Acute Pain. <i>Pain Medicine</i> , 2012, 13, S12-S20.	1.9	19
47	Methadone-related deaths. <i>Journal of Opioid Management</i> , 2005, 1, 211-217.	0.5	19
48	The Economic Impact of Opioid Use in the Management of Chronic Nonmalignant Pain. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2015, 21, 891-899.	0.9	18
49	A double-blind, placebo-controlled study of dual-opioid treatment with the combination of morphine plus oxycodone in patients with acute postoperative pain. <i>Journal of Opioid Management</i> , 2010, 6, 329-340.	0.5	18
50	Comparison of Subjective Effects of Extended-Release Versus Immediate-Release Oxycodone/Acetaminophen Tablets in Healthy Nondependent Recreational Users of Prescription Opioids: A Randomized Trial. <i>Postgraduate Medicine</i> , 2014, 126, 20-32.	2.0	17
51	A 12-week extension study to assess the safety and tolerability of naloxegol in patients with noncancer pain and opioid-induced constipation. <i>Journal of Opioid Management</i> , 2016, 12, 405-419.	0.5	17
52	The association of pain interference and opioid use with healthcare utilization and costs, and wage loss among adults with osteoarthritis in the United States. <i>Journal of Medical Economics</i> , 2019, 22, 1192-1201.	2.1	16
53	Evaluation of the abuse potential of difelikefalin, a selective kappaâ€opioid receptor agonist, in recreational polydrug users. <i>Clinical and Translational Science</i> , 2022, 15, 535-547.	3.1	15
54	Comparative Effects of Morning vs Evening Dosing of Extended-Release Hydromorphone on Sleep Physiology in Patients with Low Back Pain: A Pilot Study. <i>Pain Medicine</i> , 2015, 16, 460-471.	1.9	14

#	ARTICLE	IF	CITATIONS
55	Chronic Pain and the Opioid Conundrum. <i>Anesthesiology Clinics</i> , 2016, 34, 341-355.	1.4	14
56	Efficacy of Lubiprostone for the Treatment of Opioid-Induced Constipation, Analyzed by Opioid Class. <i>Pain Medicine</i> , 2018, 19, 1195-1205.	1.9	14
57	Medical Management of Chronic Low Back Pain: Efficacy and Outcomes. <i>Neuromodulation</i> , 2014, 17, 18-23.	0.8	13
58	Randomized Crossover Trial to Compare Abuse Liability of Intravenous Remimazolam Versus Intravenous Midazolam and Placebo in Recreational Central Nervous System Depressant Users. <i>Journal of Clinical Pharmacology</i> , 2020, 60, 1189-1197.	2.0	13
59	Safety and Efficacy of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Chronic Non-Cancer Pain Receiving Opioid Therapy: A Subgroup Analysis of Patients ≥65 Years of Age. <i>Drugs and Aging</i> , 2020, 37, 271-279.	2.7	13
60	Intravenous abuse potential study of oxycodone alone or in combination with naltrexone in nondependent recreational opioid users. <i>American Journal of Drug and Alcohol Abuse</i> , 2016, 42, 539-549.	2.1	12
61	A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Intranasal Drug Liking Study on a Novel Abuse-Deterrent Formulation of Morphine-ARER. <i>Pain Medicine</i> , 2016, 18, pnw213.	1.9	12
62	Human Abuse Potential of an Abuse-Deterrent (AD), Extended-Release (ER) Morphine Product Candidate (Morphine-ADER Injection-Molded Tablets) vs Extended-Release Morphine Administered Intranasally in Nondependent Recreational Opioid Users. <i>Pain Medicine</i> , 2016, 18, pnw219.	1.9	12
63	Human Abuse Potential of an Abuse-Deterrent (AD), Extended-Release (ER) Morphine Product Candidate (Morphine-ADER Injection-Molded Tablets) versus Extended-Release Morphine Administered Orally in Nondependent Recreational Opioid Users. <i>Pain Medicine</i> , 2016, 18, pnw174.	1.9	12
64	An Online Survey of Patients'™ Experiences Since the Rescheduling of Hydrocodone: The First 100 Days. <i>Pain Medicine</i> , 2016, 17, 1686-1693.	1.9	12
65	Treatment with Naloxegol Versus Placebo: Pain Assessment in Patients with Noncancer Pain and Opioid-Induced Constipation. <i>Pain Practice</i> , 2018, 18, 505-514.	1.9	12
66	Dilemma of Addiction and Respiratory Depression in the Treatment of Pain: A Prototypical Endomorphin as a New Approach. <i>Pain Medicine</i> , 2020, 21, 992-1004.	1.9	12
67	A Longitudinal Study of the Association of Opioid Use with Change in Pain Interference and Functional Limitations in a Nationally Representative Cohort of Adults with Osteoarthritis in the United States. <i>Advances in Therapy</i> , 2020, 37, 819-832.	2.9	12
68	Eight Principles for Safer Opioid Prescribing. <i>Pain Medicine</i> , 2013, 14, 959-961.	1.9	11
69	Oral methylnaltrexone does not negatively impact analgesia in patients with opioid-induced constipation and chronic noncancer pain. <i>Journal of Pain Research</i> , 2018, Volume 11, 1503-1510.	2.0	11
70	Efficacy and safety of a sublingual buprenorphine/naloxone rapidly dissolving tablet for the treatment of adults with opioid dependence: A randomized trial. <i>Journal of Addictive Diseases</i> , 2016, 35, 325-338.	1.3	10
71	Desmetramadol Has the Safety and Analgesic Profile of Tramadol Without Its Metabolic Liabilities: Consecutive Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Trials. <i>Journal of Pain</i> , 2019, 20, 1218-1235.	1.4	10
72	Eight principles for safer opioid prescribing and cautions with benzodiazepines. <i>Postgraduate Medicine</i> , 2015, 127, 27-32.	2.0	9

#	ARTICLE	IF	CITATIONS
73	Measurement of Drug Liking in Abuse Potential Studies: A Comparison of Unipolar and Bipolar Visual Analog Scales. <i>Journal of Clinical Pharmacology</i> , 2017, 57, 266-274.	2.0	9
74	The Physiology and Maintenance of Respiration: A Narrative Review. <i>Pain and Therapy</i> , 2020, 9, 467-486.	3.2	9
75	Abuse Potential with Oral Route of Administration of a Hydrocodone Extended-Release Tablet Formulated with Abuse-Deterrence Technology in Nondependent, Recreational Opioid Users. <i>Pain Medicine</i> , 2017, 18, 61-77.	1.9	8
76	Ending Unnecessary Opioid-Related Deaths: A National Priority. <i>Pain Medicine</i> , 2011, 12, S13-S15.	1.9	7
77	Opioid Titration and Conversion in Patients Receiving Morphine Sulfate and Naltrexone Hydrochloride Extended Release Capsules. <i>Postgraduate Medicine</i> , 2011, 123, 155-164.	2.0	7
78	Methadone Side Effects: Constipation, Respiratory Depression, Sedation, Sleep-Disordered Breathing, and the Endocrine System. , 2013, , 39-49.		7
79	Opioid abuse-deterrent strategies: role of clinicians in acute pain management. <i>Postgraduate Medicine</i> , 2016, 128, 76-84.	2.0	7
80	Intranasal Pharmacokinetics of Morphine ARER, a Novel Abuse-Deterrent Formulation: Results from a Randomized, Double-Blind, Four-Way Crossover Study in Nondependent, Opioid-Experienced Subjects. <i>Pain Research and Management</i> , 2018, 2018, 1-10.	1.8	7
81	<p>A Renal Impairment Subgroup Analysis of the Safety and Efficacy of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Chronic Non-Cancer Pain Receiving Opioid Therapy</p>. <i>Journal of Pain Research</i> , 2020, Volume 13, 605-612.	2.0	7
82	Unintended Harm from Opioid Prescribing Guidelines. <i>Pain Medicine</i> , 2009, 10, 285-286.	1.9	6
83	Oral methylnaltrexone is efficacious and well tolerated for the treatment of opioid-induced constipation in patients with chronic noncancer pain receiving concomitant methadone. <i>Journal of Pain Research</i> , 2018, Volume 11, 2509-2516.	2.0	6
84	A PhaseÂl Placebo-Controlled Trial Comparing the Effects of Buprenorphine Buccal Film and Oral Oxycodone Hydrochloride Administration on Respiratory Drive. <i>Advances in Therapy</i> , 2020, 37, 4685-4696.	2.9	6
85	Naldemedine Improves Patient-Reported Outcomes of Opioid-Induced Constipation in Patients with Chronic Non-Cancer Pain in the COMPOSE Phase 3 Studies. <i>Journal of Pain Research</i> , 2021, Volume 14, 2179-2189.	2.0	6
86	Establishing Minimal Clinically Important Differences in Quality of Life Measures in Opioid-Induced Constipation. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 855-863.	4.4	6
87	Oxycodone extended-release using gel-cap technology to resist alteration and abuse for the treatment of moderate-to-severe pain. <i>Pain Management</i> , 2011, 1, 417-425.	1.5	5
88	American Academy of Pain Medicine Response to PROP Petition to the FDA That Seeks to Limit Pain Medications for Legitimate Noncancer Pain Sufferers. <i>Pain Medicine</i> , 2012, 13, 1259-1264.	1.9	5
89	Effects of concurrent intravenous morphine sulfate and naltrexone hydrochloride on end-tidal carbon dioxide. <i>Harm Reduction Journal</i> , 2012, 9, 13.	3.2	5
90	Pharmacokinetics and Abuse Potential of Benzhydrocodone, a Novel Prodrug of Hydrocodone, After Intranasal Administration in Recreational Drug Users. <i>Pain Medicine</i> , 2018, 19, 2438-2449.	1.9	5

#	ARTICLE	IF	CITATIONS
91	A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Intranasal Human Abuse Potential Study of Oxycodone ARIR, a Novel, Immediate-Release, Abuse-Deterrent Formulation. Pain Medicine, 2019, 20, 747-757.	1.9	5
92	Atypical opioids and their effect on respiratory drive. Journal of Opioid Management, 2021, 17, 109-118.	0.5	5
93	Correlation of Subjective Effects with Systemic Opioid Exposure from Fixed-Dose Combinations of Oxycodone/Acetaminophen in Recreational Users of Prescription Drugs. Pain Medicine, 2015, 17, n/a-n/a.	1.9	4
94	Human abuse potential of immediate-release/extended-release versus immediate-release hydrocodone bitartrate/acetaminophen: a randomized controlled trial in recreational users of prescription opioids. Postgraduate Medicine, 2015, 127, 13-21.	2.0	3
95	Real-world misuse, abuse, and dependence of abuse-deterrent versus non-abuse-deterrent extended-release morphine in Medicaid non-cancer patients. Postgraduate Medicine, 2019, 131, 225-229.	2.0	3
96	Extended-release morphine sulfate and naltrexone hydrochloride (EMBEDA): naltrexone-associated withdrawal and abuse-related effects in patients with chronic pain and recreational opioid users. Current Medical Research and Opinion, 2019, 35, 503-512.	1.9	3
97	Open-Label Adhesion Performance Studies of a New Lidocaine Topical System 1.8% versus Lidocaine Patches 5% and Lidocaine Medicated Plaster 5% in Healthy Subjects. Journal of Pain Research, 2021, Volume 14, 513-526.	2.0	3
98	Randomized, double-blind, placebo-controlled and active-controlled study to assess the relative abuse potential of oxycodone HCl-niacin tablets compared with oxycodone alone in nondependent, recreational opioid users. Substance Abuse and Rehabilitation, 2012, 3, 101.	4.8	2
99	Safety profile of extended-release morphine sulfate with sequestered naltrexone hydrochloride in older patients: pooled analysis of three clinical trials. Current Medical Research and Opinion, 2016, 32, 563-572.	1.9	2
100	Human abuse potential studies of abuse-deterrent opioids: lessons from oral and intranasal studies with morphine abuse-deterrent, extended-release, injection-molded tablets. Current Medical Research and Opinion, 2018, 34, 893-901.	1.9	2
101	Relative Oral Bioavailability of an Abuse-Deterrent, Immediate-Release Formulation of Oxycodone, Oxycodone ARIR in a Randomized Study. Advances in Therapy, 2019, 36, 1730-1740.	2.9	2
102	Interpreting labels of abuse-deterrent opioid analgesics. Journal of Opioid Management, 2017, 13, 415-423.	0.5	2
103	Poster 526 Abuse Quotient of Orally Administered MNK-795 Extended-Release Oxycodone/Acetaminophen Tablets vs Immediate-Release Oxycodone/Acetaminophen Tablets in Recreational Users of Prescription Opioids. PM and R, 2014, 6, S370-S371.	1.6	1
104	Effects of intravenous oxycodone alone or in combination with naltrexone on measures of respiratory depression: a randomized placebo-controlled study. Therapeutic Advances in Drug Safety, 2019, 10, 204209861882127.	2.4	1
105	Ventilatory Response to Hypercapnia as Experimental Model to Study Effects of Oxycodone on Respiratory Depression. Current Clinical Pharmacology, 2021, 16, .	0.6	1
106	Insights and issues from FDA Advisory Committee meetings on abuse-deterrent opioids. Journal of Opioid Management, 2017, 13, 379-389.	0.5	1
107	Risk Mitigation Strategies. , 2016, , 163-180.		1
108	A nasal abuse potential randomized clinical trial of REMOXYÂ® ER, a high-viscosity extended-release oxycodone formulation. Journal of Opioid Management, 2018, 14, 437-443.	0.5	1

#	ARTICLE	IF	CITATIONS
109	Effects of buprenorphine buccal film and oral oxycodone on pupil diameter in a respiratory study. Journal of Opioid Management, 2022, 18, 181-190.	0.5	1
110	Pharmacokinetics of Buprenorphine Buccal Film and Orally-administered Oxycodone in a Respiratory Study: An Analysis of Secondary Outcomes from a Randomized Controlled Trial. Pain and Therapy, 2022, 11, 817-825.	3.2	1
111	It Takes Many True Leaders to Become a Top-Tier Pain Organization. Pain Medicine, 2014, 15, 3-3.	1.9	0
112	Poster 427 Pharmacodynamic Effects From a Category 3 Intranasal Human Abuse Potential Study of an Abuse-Deterrent, Extended-Release Morphine Product Candidate in Nondependent, Recreational Opioid Users. PM and R, 2016, 8, S300-S301.	1.6	0
113	Opioid-sparing Effects of SoluMatrix Indomethacin in a Phase 3 Study in Patients With Acute Postoperative Pain. Clinical Journal of Pain, 2018, 34, 138-144.	1.9	0
114	Evaluation of the Relative Intranasal Abuse Potential of a Hydrocodone Extended-Release Tablet Formulated with Abuse-Deterrence Technology in Nondependent, Recreational Opioid Users. Pain Medicine, 2018, 19, 1597-1612.	1.9	0
115	The Prescription Drug Abuse Epidemic and Emerging Prescribing Guidelines. , 2018, , 389-394.e1.		0
116	Doctor driven problem or doctor driven solution?. Journal of Opioid Management, 2017, 13, 351-352.	0.5	0
117	Pharmacogenetics of Pain: The Future of Personalized Medicine. , 2018, , 435-445.		0
118	Drug trafficking, good faith, and legal standards to convict: How the United States Supreme Court is about to affect every prescriber in America. Journal of Opioid Management, 2022, 18, 203-204.	0.5	0